# TAEK-VAC-HerBy Vaccine for Brachyury and HER2 Expressing Cancer

> **NCT04246671** · PHASE1 · COMPLETED · sponsor: **Bavarian Nordic** · enrollment: 37 (actual)

## Conditions studied

- Chordoma
- HER2-positive Breast Cancer

## Interventions

- **BIOLOGICAL:** TAEK-VAC-HerBy

## Key facts

- **NCT ID:** NCT04246671
- **Lead sponsor:** Bavarian Nordic
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-08-10
- **Primary completion:** 2024-02-17
- **Final completion:** 2024-12-11
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2025-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04246671

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04246671, "TAEK-VAC-HerBy Vaccine for Brachyury and HER2 Expressing Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04246671. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*